Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...

HLD-0915 has received FDA fast track designation for mCRPC, expediting its development and review process to address unmet medical needs. Halda Therapeutics is conducting a phase 1/2 clinical trial to ...

Here’s how to get relief from the nausea, anxiety, pain, and other symptoms of advanced prostate cancer and its treatments. Palliative care can make life more manageable during cancer treatment, but ...

In this context, "claims evaluated" refers to how ProstAfense presents and explains its own formulation approach and ingredient structure, rather than a comparative or third-party product review.